Neuronal damage; IL-18, IL-1β, and TNF-α protein expressions; mRNA expressions of these proteins; Nerve growth factor (NGF), Brain-derived neurotropic factor (BDNF), and Neurotrophin-3 (NT3) expressions were dramatically decreased when treated with BAY-117082 at 5 mg/kg and 10 mg/kg. These report suggesting that it significantly modulated Erk/CREB/Akt pathways and could be considered novel strategy therapeutics for migraine treatment. This evidence concerns the gene AKT1 and migraine disorder.